5月26日中银创新医疗混合C净值下跌2.04%，近1个月累计下跌0.28%

Group 1 - The core point of the article highlights the performance of the Zhongyin Innovation Medical Mixed Fund C, which has a latest net value of 1.6494 yuan, reflecting a decrease of 2.04% [1] - The fund's performance over the past month shows a return of -0.28%, ranking 3221 out of 3909 in its category; over the past six months, it has achieved a return of 25.90%, ranking 82 out of 3796; and since the beginning of the year, it has returned 39.14%, ranking 35 out of 3832 [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed Fund C was established on October 30, 2020, and as of March 31, 2025, it has a total scale of 1.454 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry, including roles at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund C since July 1, 2022, and has also taken on management roles for other funds within the company [2]